Headlines
Swiss biotech BioVersys gets $235 million valuation after completing flotation
Published by Global Banking & Finance Review®
Posted on February 6, 2025
2 min readLast updated: January 26, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on February 6, 2025
2 min readLast updated: January 26, 2026
Swiss biotech BioVersys completes IPO, reaching a $235 million valuation. Funds will develop treatments for drug-resistant infections.
ZURICH (Reuters) - Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million Swiss francs ($235.46 million).
Just over 2.2 million shares were placed by the Basel-based company in the all-primary offering at 36 francs per share, it said on Thursday.
Trading is due to start on Friday, with the stock expected to be included on the Swiss Performance Index on February 10.
BioVersys researches and develops novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria.
It raised 90 million francs from the IPO, which will used towards the development of its BV100 treatment for infections linked to ventilator-associated pneumonia and bloodstream infections.
Some of the money will be used for its tuberculosis product alpibectir, which BioVersys is working on with GSK.
CEO Marc Gitzinger said the IPO was the next stage in the company's growth strategy.
"This support enables us to move full speed ahead with BV100 into the Phase 3 program, advance alpibectir into additional Phase 2 trials in collaboration with GSK and further progress our early stage pipeline," he said.
($1 = 0.9046 Swiss francs)
(Reporting by John Revill; Editing by Bernadette Baum)
BioVersys researches and develops novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria.
BioVersys raised 90 million francs from the IPO, which will be used towards the development of its BV100 treatment for infections.
The funds will be allocated to advance the BV100 treatment into Phase 3 trials and further develop the tuberculosis product alpibectir in collaboration with GSK.
Trading for BioVersys is due to start on Friday, with the stock expected to be included on the Swiss Performance Index on February 10.
CEO Marc Gitzinger stated that the IPO was the next stage in the company's growth strategy, enabling them to move forward with their treatment programs.
Explore more articles in the Headlines category
